Development of oral aprepitant-loaded chitosan-polyethylene glycol-coated cyclodextrin nanocapsules: formulation, characterization, and pharmacokinetic evaluation

Erdogar N., Akkin S., Nielsen T. T., Ozcelebi E., Erdogdu B., NEMUTLU E., ...More

JOURNAL OF PHARMACEUTICAL INVESTIGATION, vol.51, no.3, pp.297-310, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1007/s40005-020-00511-x
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE
  • Page Numbers: pp.297-310
  • Keywords: Aprepitant, Nanoparticle, Nanocapsule, Amphiphilic cyclodextrin, Neurokinin-1 receptor antagonist, Chemotherapy-induced nausea and vomiting
  • Hacettepe University Affiliated: Yes


Purpose Aprepitant (APRT), a selective neurokinin 1 antagonist, is clinically used in the prevention of acute and delayed chemotherapy-induced nausea and vomiting. The low solubility of APRT, which limits its oral bioavailability, is overcome by nanonization. This study aimed to design and evaluate novel in vitro and in vivo chitosan (CS)-polyethylene glycol (PEG)-coated cyclodextrin (CD) nanoparticles and nanocapsules to enhance the solubility and oral bioavailability of APRT.